4
Changes in Ownership
Eloxx Pharmaceuticals, Inc. Filed Acc 0001193125-26-214890
President and CEO acquired 472,826 shares (option exercise)
- President and CEO acquired 1,000,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Aggarwal Sumit · President and CEO
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-08-14 | Exercise or conversion : show line 1 in the form | +196,880 | $0.00 | $20 | 396,810 | D |
| 2025-09-19 | Grant or award : show line 2 in the form | +1,000,000 | 1,396,810 | D | ||
| 2026-01-24 | Exercise or conversion : show line 3 in the form | +15,000 | 1,411,810 | D | ||
| 2026-02-28 | Exercise or conversion : show line 4 in the form | +260,946 | $0.15 | $39,142 | 1,672,756 | D |
Table II: Derivative
16 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-02-06 | Grant or award : show line 5 in the form Stock Option (Right to Buy) | +42,790 | 42,790 | D |
| 2024-10-16 | Returned to the company : show line 6 in the form Stock Option (Right to Buy) | −42,790 | 0 | D |
| 2024-10-16 | Grant or award : show line 7 in the form Stock Option (Right to Buy) | +42,790 | 42,790 | D |
| 2024-10-16 | Returned to the company : show line 8 in the form Stock Option (Right to Buy) | −35,580 | 0 | D |
| 2024-10-16 | Grant or award : show line 9 in the form Stock Option (Right to Buy) | +35,580 | 35,580 | D |
| 2024-10-16 | Returned to the company : show line 10 in the form Stock Option (Right to Buy) | −24,810 | 0 | D |
| 2024-10-16 | Grant or award : show line 11 in the form Stock Option (Right to Buy) | +24,810 | 24,810 | D |
| 2024-10-16 | Returned to the company : show line 12 in the form Stock Option (Right to Buy) | −68,700 | 0 | D |
Loading xslF345X06/ownership.xml…